BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17286527)

  • 1. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.
    Tiwari A; Tseng CL; Kern EF; Maney M; Miller DR; Pogach L
    Am J Manag Care; 2007 Feb; 13(2):73-9. PubMed ID: 17286527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
    Penne EL; Neumann J; Klein IH; Oey PL; Bots ML; Blankestijn PJ
    J Nephrol; 2009; 22(2):208-15. PubMed ID: 19384838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
    Inoue A; Babazono T; Iwamoto Y
    Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
    Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usual ACE inhibitor therapy in CKD patients is associated with lower plasma aldosterone levels than usual angiotensin receptor blocker therapy.
    Haddad N; Rajan J; Nagaraja HN; Agarwal AK; Hebert LA
    Kidney Blood Press Res; 2007; 30(5):299-305. PubMed ID: 17641546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
    Levin A; Djurdjev O; Beaulieu M; Er L
    Am J Kidney Dis; 2008 Oct; 52(4):661-71. PubMed ID: 18805347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
    Thilly N; Bayat S; Alla F; Kessler M; Briançon S; Frimat L
    Clin Transplant; 2008; 22(4):439-46. PubMed ID: 18318741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
    Brackbill ML; Bashaw-Keaton R; Sytsma CS
    Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
    Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
    Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
    Rutkowski M; Mann W; Derose S; Selevan D; Pascual N; Diesto J; Crooks P
    Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.